Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

PELO negatively regulates HER receptor signalling and metastasis

Oncogene volume 33, pages 1190–1197 (2014)Cite this article

Subjects

Abstract

The HER family is composed of four receptor tyrosine kinases, which are frequently deregulated in several types of cancer. Activated HER receptors initiate intracellular signalling pathways by attracting to the plasma membrane a plethora of adaptor and signalling molecules. Although there are more than a dozen HER-interacting proteins that regulate signal transduction and have been extensively studied, recent proteomic studies have shown the existence of many novel but largely uncharacterized factors that may bind HER receptors. In this report, we describe a cell-based identification of several new HER2-binding proteins, including HAX1, YWHAZ, PELO and ACP1. Analysis of these factors showed that one of them, PELO, binds to active HER2 and epidermal growth factor receptor and thereby attenuates phosphatidylinositol 3-kinase (PI3K)/AKT signalling, likely through regulation of the recruitment of p85-PI3K to activated receptor. Functional characterization of PELO showed that it negatively regulates cell migration and metastasis in vivo. These results reveal that PELO is a novel regulator of HER-signalling and therefore is likely to have a role in inhibiting tumour progression and invasion.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Citri A, Yarden Y . EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505–516.

    Article  CAS  Google Scholar 

  2. Yaffe MB . Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol 2002; 3: 177–186.

    Article  CAS  Google Scholar 

  3. Hynes NE, MacDonald G . ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21: 177–184.

    Article  CAS  Google Scholar 

  4. Segatto O, Anastasi S, Alema S . Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J Cell Sci 2011; 124: 1785–1793.

    Article  CAS  Google Scholar 

  5. Yarden Y, Pines G . The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012; 12: 553–563.

    Article  CAS  Google Scholar 

  6. Engelman JA . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550–562.

    Article  CAS  Google Scholar 

  7. Jones RB, Gordus A, Krall JA, MacBeath G . A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006; 439: 168–174.

    Article  CAS  Google Scholar 

  8. Morandell S, Stasyk T, Skvortsov S, Ascher S, Huber LA . Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics 2008; 8: 4383–4401.

    Article  CAS  Google Scholar 

  9. Schulze WX, Deng L, Mann M . Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005; 1: 2005–0008.

    Article  Google Scholar 

  10. Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramon C et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009; 29: 3319–3331.

    Article  CAS  Google Scholar 

  11. Eberhart CG, Wasserman SA . The pelota locus encodes a protein required for meiotic cell division: an analysis of G2/M arrest in Drosophila spermatogenesis. Development 1995; 121: 3477–3486.

    CAS  PubMed  Google Scholar 

  12. Davis L, Engebrecht J . Yeast dom34 mutants are defective in multiple developmental pathways and exhibit decreased levels of polyribosomes. Genetics 1998; 149: 45–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Adham IM, Sallam MA, Steding G, Korabiowska M, Brinck U, Hoyer-Fender S et al. Disruption of the pelota gene causes early embryonic lethality and defects in cell cycle progression. Mol Cell Biol 2003; 23: 1470–1476.

    Article  CAS  Google Scholar 

  14. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 2003; 278: 13829–13837.

    Article  CAS  Google Scholar 

  15. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008; 68: 2366–2374.

    Article  CAS  Google Scholar 

  16. Baselga J, Swain SM . Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463–475.

    Article  CAS  Google Scholar 

  17. Rodrigues GA, Falasca M, Zhang Z, Ong SH, Schlessinger J . A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol Cell Biol 2000; 20: 1448–1459.

    Article  CAS  Google Scholar 

  18. Stover DR, Becker M, Liebetanz J, Lydon NB . Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem 1995; 270: 15591–15597.

    Article  CAS  Google Scholar 

  19. Moasser MM, Basso A, Averbuch SD, Rosen N . The tyrosine kinase inhibitor ZD1839 (‘Iressa’) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61: 7184–7188.

    CAS  PubMed  Google Scholar 

  20. Oppel F, Muller N, Schackert G, Hendruschk S, Martin D, Geiger KD et al. SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells. Mol Cancer 2011; 10: 137.

    Article  CAS  Google Scholar 

  21. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537–549.

    Article  CAS  Google Scholar 

  22. Mukherjee M, Chow SY, Yusoff P, Seetharaman J, Ng C, Sinniah S et al. Structure of a novel phosphotyrosine-binding domain in Hakai that targets E-cadherin. EMBO J 2012; 31: 1308–1319.

    Article  CAS  Google Scholar 

  23. Burnicka-Turek O, Kata A, Buyandelger B, Ebermann L, Kramann N, Burfeind P et al. Pelota interacts with HAX1, EIF3G and SRPX and the resulting protein complexes are associated with the actin cytoskeleton. BMC Cell Biol 2010; 11: 28.

    Article  Google Scholar 

  24. Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609–615.

    Article  Google Scholar 

  25. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367–5374.

    Article  CAS  Google Scholar 

  26. Blagoev B, Kratchmarova I, Ong SE, Nielsen M, Foster LJ, Mann M . A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat Biotechnol 2003; 21: 315–318.

    Article  CAS  Google Scholar 

  27. Garcia-Castillo J, Pedersen K, Angelini PD, Bech-Serra JJ, Colome N, Cunningham MP et al. HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation. J Biol Chem 2009; 284: 25302–25313.

    Article  CAS  Google Scholar 

  28. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518–521.

    Article  CAS  Google Scholar 

  29. TCGA, Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70.

    Article  Google Scholar 

  30. TCGA, Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519–525.

    Article  Google Scholar 

  31. TCGA, Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609–615.

    Article  Google Scholar 

  32. Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010; 19: 98–110.

    Article  Google Scholar 

  33. TCGA, Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–337.

    Article  Google Scholar 

  34. Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by the Instituto de Salud Carlos III (Intrasalud PI081154 and the network of cooperative cancer research (RTICC-RD06/0020/0022)), the Breast Cancer Research Foundation, the Asociación Española Contra el Cancer (AECC) and AVON Foundation. KP was supported by the postdoctoral program from the AECC.

Author information

Authors and Affiliations

  1. Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

    K Pedersen, F Canals & J Arribas

  2. Translational Genomics Research Program, VHIO, Barcelona, Spain

    A Prat

  3. Clinical Research Program, VHIO, Barcelona, Spain

    J Tabernero

  4. Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Campus de la UAB, Bellaterra, Spain

    J Arribas

  5. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

    J Arribas

Authors
  1. K Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Canals
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Prat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Tabernero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Arribas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to K Pedersen or J Arribas.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pedersen, K., Canals, F., Prat, A. et al. PELO negatively regulates HER receptor signalling and metastasis. Oncogene 33, 1190–1197 (2014). https://doi.org/10.1038/onc.2013.35

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.35

Keywords

This article is cited by

Search

Advanced search

Quick links